Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CCR1 | P32246 | 4/20 | 0.41 |
| ▸ | CCR8 | P51685 | 4/20 | 0.41 |
| ▸ | CCR5 | P51681 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2805108 | 0.86 | RAB9A (0.43) | MAPTLMNAKDM4ESMN1; SMN2CCR1 | |
| SCHEMBL2808539 | 0.84 | MAPT (0.41) | MAPTLMNAKDM4ESMN1; SMN2CCR1 | |
| SCHEMBL2808536 | 0.84 | MAPT (0.41) | MAPTLMNAKDM4ESMN1; SMN2CCR1 | |
| SCHEMBL16474108 | 0.84 | MAPT (0.46) | MAPTLMNAKDM4ESMN1; SMN2CCR1 | |
| SCHEMBL2805404 | 0.81 | CCR1 (0.49) | MAPTLMNAKDM4ESMN1; SMN2CCR1 | |
| SCHEMBL2805962 | 0.77 | KDM4E (0.47) | MAPTKDM4EL3MBTL1CYP2D6TDP1 | |
| SCHEMBL2808270 | 0.77 | CCR1 (0.55) | MAPTLMNAKDM4ESMN1; SMN2CCR1 | |
| SCHEMBL2808990 | 0.77 | CCR1 (0.39) | MAPTLMNAKDM4ESMN1; SMN2CCR1 | |
| SCHEMBL2805086 | 0.76 | CCR1 (0.43) | MAPTLMNAKDM4ESMN1; SMN2CCR1 | |
| SCHEMBL2809550 | 0.73 | CCR1 (0.40) | MAPTLMNAKDM4ESMN1; SMN2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140011835-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2014-01-09 | — | — | US | claimed |
| US-20140011835-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2014-01-09 | — | — | US | disclosed |
| US-20140011835-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2014-01-09 | — | — | US | disclosed |
| US-20140011835-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2014-01-09 | — | — | US | disclosed |
| US-8592446-B2 | [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases | NOSCIRA, S.A. (ES) | 2013-11-26 | — | — | US | disclosed |
| US-20100240692-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2010-09-23 | — | — | US | disclosed |
| US-20100240692-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2010-09-23 | — | — | US | disclosed |
| US-20100240692-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2010-09-23 | — | — | US | disclosed |
| EP-2170464-A2 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008152068-A2 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152068-A2 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2008-12-18 | — | — | WO | disclosed |
| EP-2002863-A1 | [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases | NOSCIRA, S.A. (ES) | 2008-12-17 | — | — | EP | disclosed |
| EP-2002863-A1 | [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases | NOSCIRA, S.A. (ES) | 2008-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011835-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | HTT, PARK7, ATXN10 | MAPT 53/4885LMNA 1711/4885KDM4E 1412/4885 |
| US-20100240692-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | HTT, ATXN10, PSEN1 | MAPT 24/4885LMNA 1049/4885KDM4E 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.